Company intelligence
ERS Genomics
The global CRISPR/Cas9 licensing leader
About ERS Genomics
ERS Genomics was formed to commercialise the foundational CRISPR-Cas9 intellectual property held by co-inventor, co-owner and Nobel Prize-winner Dr. Emmanuelle Charpentier. Licenses are available in multiple fields of use. CRISPR-Cas9 is a revolutionary new genome editing technology, which offers significant advantages in speed, efficiency and cost over earlier genome editing methods. Our team has decades of experience in the field of genome editing and its application, in business development and licensing, licensing preclinical and clinical stage therapeutic products and drug delivery technologies, genome editing technologies as well as overseeing research and development. To learn more about acquiring your license, contact us today.
Verified activity
Signals from ERS Genomics
4 published signals
Research & Knowledge
ERS Genomics CEO John E. Milad explores how the shift from bespoke experimentation towards engineering discipline is changing the next phase of synthetic biology in the latest Monthly Cut.
Reported by ERS Genomics
Research & Knowledge
ERS Genomics published a new drug-design framework that learns directly from every compound synthesised in the lab, including failures and candidates rejected on developability grounds.
Reported by John E. Milad
Research & Knowledge
ERS Genomics CEO John E. Milad explores how CRISPR has become part of the core toolkit of synthetic biology and industrial bioproduction in The Monthly Cut
Reported by ERS Genomics
Research & Knowledge
ERS Genomics published an article exploring challenges in synthetic biology and biomanufacturing in The Monthly Cut, The SynBio Scale-Up
Reported by John E. Milad